In the news release, DarioHealth Announces New Blue Cross Blue Shield Agreement, Expanding Health Plan Client Base, issued 06-Feb-2025 by DarioHealth Corp. over PR Newswire, we are advised by the company to make multiple changes to the press release. The complete, corrected release follows:

DarioHealth expands its payer network with a new regional health plan, an affiliate of one of the top 10 national health plans, bolstering recurring revenue growth and reinforcing its position in one of healthcare's fastest-growing sectors; Dario's AI-driven digital health platform continues to drive adoption among payers seeking scalable, data-driven solutions

NEW YORK, March 17, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that it has secured a new agreement with a large regional health plan, marking a significant expansion of its presence in the health plan market. The program, rolled out in January 2025, allows members seamless access to Dario's evidence-based, AI-driven health coaching and monitoring tools.

This agreement will integrate the Dario platform's comprehensive cardiometabolic digital health solutions, including programs for diabetes, hypertension, and weight management, into the health plan's suite of member services offered to employers. The agreement is already contributing to the Company's annual recurring revenue (ARR) in Q1 2025, and as with many of the contracts launched in January of 2025, the relationship with this health plan is expected to expand further throughout the year to cover more of the plan's population.

This new plan is an affiliate of a trusted leader in healthcare across the U.S., which reinforces Dario's expanding role in delivering digital cardiometabolic care solutions nationwide. With this agreement, Dario now serves nine health plans, spanning both regional and national payers. As the cardiometabolic disease market is projected to surpass $1.2 trillion by 2033¹, this latest expansion strengthens Dario's position in one of healthcare's fastest growing and most financially significant sectors.

"We believe that this expansion highlights the increasing demand among payers for scalable, AI-driven digital health solutions that deliver measurable health improvements and cost efficiencies," said Steven Nelson, Chief Commercial Officer at Dario. " We believe that securing this health plan further validates our market leadership in cardiometabolic care and reinforces our ability to scale recurring revenue growth. With nine health plans now leveraging our technology, we are rapidly expanding our presence in the multi-billion-dollar payer market and   strengthening our trajectory toward profitability and long-term growth."

About DarioHealth Corp.

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the integration of the Dario platform's digital health solutions into the regional health plan, the expectancy that the collaborations with the Company's current health plans will expand further throughout the year to cover more populations, the Company's expanding role in delivering digital cardiometabolic care solutions nationwide, projections with respect to the cardiometabolic disease market, the increasing demand among payers for scalable, AI-driven digital health solutions, and the Company's ability to scale recurring revenue growth, profitability and long-term growth. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

¹https://straitsresearch.com/report/cardiometabolic-disease-market

DarioHealth Corporate Contact
Mary Mooney
VP Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1-312-593-4280

DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
+315-378-6922